Chinese biotech dominance in R&D is on the rise
Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...
AZN INVESTOR ALERT: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
If you suffered substantial losses and wish to serve as lead plaintiff of the AstraZeneca class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or ...
Relay Therapeutics' SWOT analysis: stock poised for growth amid fierce competition
Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, ...
AstraZeneca said to have changed management of its China unit
AstraZeneca (AZN) changes key management roles in China as the company emerges from several scandals involving its executives ...
Guggenheim lifts AstraZeneca stock target, buy rating on prospects
Guggenheim adjusted its price target on shares of AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), increasing it to GBP13,100 from ...
AstraZeneca's Calquence gains FDA nod for 1L MCL treatment
AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $207.67 billion and ...
AstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S.
AstraZeneca (AZN) stock in focus as the U.S. FDA expands approval for its lymphoma therapy Calquence with chemoimmunotherapy ...
FDA approves new mantle cell lymphoma treatment
WASHINGTON - The U.S. Food and Drug Administration has granted approval to AstraZeneca (NASDAQ:AZN)'s Calquence ...
Absci stock reiterated at Buy at H.C. Wainwright on AI-drug discovery leadership
H.C. Wainwright maintained a positive stance on Absci Corp (NASDAQ:ABSI), with an analyst from the firm reiterating a Buy rating and a price target of $7.00.
Innate Pharma shares retain Buy rating on long-term strategy
H.C. Wainwright reaffirmed its Buy rating and $25.00 price target on shares of Innate Pharma (EPA:IPH) S.A. (NASDAQ:IPHA), ...
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...
SpringWorks Therapeutics' SWOT analysis: biotech stock shows promise amid challenges
SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company with a market capitalization of $2.66 billion focused ...